These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 28242627)

  • 1. New concepts in the management of restless legs syndrome.
    Garcia-Borreguero D; Cano-Pumarega I
    BMJ; 2017 Feb; 356():j104. PubMed ID: 28242627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
    Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
    Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Concepts of the Pathophysiology and Adverse Outcomes of Restless Legs Syndrome.
    Romero-Peralta S; Cano-Pumarega I; García-Borreguero D
    Chest; 2020 Sep; 158(3):1218-1229. PubMed ID: 32247713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.
    Wanner V; Garcia Malo C; Romero S; Cano-Pumarega I; García-Borreguero D
    Adv Pharmacol; 2019; 84():187-205. PubMed ID: 31229171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.
    Garcia-Borreguero D; Kohnen R; Silber MH; Winkelman JW; Earley CJ; Högl B; Manconi M; Montplaisir J; Inoue Y; Allen RP
    Sleep Med; 2013 Jul; 14(7):675-84. PubMed ID: 23859128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of treatment failure in restless legs syndrome (Willis-Ekbom disease).
    Garcia-Borreguero D; Cano-Pumarega I; Marulanda R
    Sleep Med Rev; 2018 Oct; 41():50-60. PubMed ID: 29602660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of restless leg syndrome (Willis-Ekbom disease) during long-term dopaminergic treatment.
    Garcia-Borreguero D; Benitez A; Kohnen R; Allen R
    Postgrad Med; 2015; 127(7):716-25. PubMed ID: 26077324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on restless legs syndrome (Willis-Ekbom disease): clinical features, pathogenesis and treatment.
    Garcia-Borreguero D; Williams AM
    Curr Opin Neurol; 2014 Aug; 27(4):493-501. PubMed ID: 24978636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Living with Restless Legs Syndrome/Willis-Ekbom Disease.
    Tachibana N
    Sleep Med Clin; 2015 Sep; 10(3):359-67, xv. PubMed ID: 26329446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the treatment of Restless Legs Syndrome/Willis-Ekbom Disease: prospects and challenges.
    Zucconi M; Galbiati A; Rinaldi F; Casoni F; Ferini-Strambi L
    Expert Rev Neurother; 2018 Sep; 18(9):705-713. PubMed ID: 30095315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Restless Legs Syndrome: from Mechanisms to Treatment.
    Gonzalez-Latapi P; Malkani R
    Curr Neurol Neurosci Rep; 2019 Jun; 19(8):54. PubMed ID: 31250128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restless legs syndrome.
    Klingelhoefer L; Bhattacharya K; Reichmann H
    Clin Med (Lond); 2016 Aug; 16(4):379-82. PubMed ID: 27481386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restless legs syndrome/Willis Ekbom disease: evaluation and treatment.
    Allen RP
    Int Rev Psychiatry; 2014 Apr; 26(2):248-62. PubMed ID: 24892899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willis-Ekbom Disease or Restless Legs Syndrome?
    Carlos K; Prado LB; Carvalho LB; Prado GF
    Sleep Med; 2015 Sep; 16(9):1156-9. PubMed ID: 26298794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
    Geyer J; Bogan R
    Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome.
    Silber MH; Becker PM; Earley C; Garcia-Borreguero D; Ondo WG;
    Mayo Clin Proc; 2013 Sep; 88(9):977-86. PubMed ID: 24001490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic Treatment of Restless Legs Syndrome.
    Lv Q; Wang X; Asakawa T; Wang XP
    Curr Neuropharmacol; 2021; 19(3):372-382. PubMed ID: 33380302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restless Leg Syndrome Across the Globe: Epidemiology of the Restless Legs Syndrome/Willis-Ekbom Disease.
    Koo BB
    Sleep Med Clin; 2015 Sep; 10(3):189-205, xi. PubMed ID: 26329429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of the restless legs Syndrome/Willis-Ekbom disease among teenagers, its clinical characteristics and impact on everyday functioning.
    Pienczk-Ręcławowicz K; Pilarska E; Olszewska A; Ręcławowicz D; Konieczna S; Sławek J
    Sleep Med; 2022 Jan; 89():48-54. PubMed ID: 34883398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancing synthetic therapies for the treatment of restless legs syndrome.
    de Biase S; Pellitteri G; Gigli GL; Valente M
    Expert Opin Pharmacother; 2019 Nov; 20(16):1971-1980. PubMed ID: 31424287
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.